

## PATENT

- D1 SUB B1
1. (Twice Amended) A neuronal cell line obtained from a transgenic rat, the cells of which comprise:  
(i) a conditional oncogene, transforming gene or immortalizing gene or a cell cycle affecting gene operably linked to  
(ii) a cell type specific promoter.

D2

4. (Twice Amended) F The cell line of claim 1 in which the cell type specific promoter is a human NF-L gene promoter.

D3

6. (Twice Amended) The cell line of claim 1 or 4 in which the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene.

SUB B2

7. (Twice Amended) The cell line of claim 1 or 4 in which the conditional oncogene, transforming gene, immortalising gene or the cell cycle affecting gene is a C Erb  $\beta$  2 gene or a TGF  $\alpha$  gene.

D4

19. (Twice Amended) A method of testing a material suspected of being a carcinogen, said method comprising subjecting a rat according to claim 17 or 18 to said material and detecting neoplasms as an indication of carcinogenicity.

20. (Twice Amended) A method of testing a material suspected of conferring protection against the development of neoplasms, said method comprising administering said material to a rat according to claim 17 or 18 and detecting a reduced incidence of development of neoplasms, compared to an untreated rat, as an indication of said protection.

---

PATENT

*SUB E7*  
*D5*

30. (New) The method of claim 13 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb  $\beta$ 2 gene or a TGF  $\alpha$  gene and wherein the cell type specific promoter is a human NF-L gene promoter.

31. (New) The transgenic rat of claim 18 wherein the cell type specific promoter is a human NF-L gene promoter.

*SUB E8*

32. (New) The method of claim 25 wherein the conditional oncogene, transforming gene or immortalizing gene or the cell cycle affecting gene is a SV40tsA58 gene, a C Erb  $\beta$ 2 gene or a TGF  $\alpha$  gene and wherein the cell type specific promoter is a human NF-L gene promoter.

---

REMARKS

Before amendment, claims 1, 3-4, 6-9, 13 and 15-29 were pending. After amendment, claims 1, 4, 6-9, 13 and 15-32 are pending.

A marked up of the claims indicating the changes made as a result of this amendment is attached.

**Claim Objections**

Claims 19 and 20 are objected to under 37 CFR § 1.75(c) as being in improper multiple dependent form. The claims have been amended. Accordingly, applicants believe that the objection has been obviated.